The present invention is referred to novel polymeric conjugates to which at least it is linked a fibril disruptor agent and/or a aggregates blocking agent, and additionally a targeting moiety and/or a probe for therapy and diagnosis. In the polymer-drug conjugate, the polymeric platform transports at least one bioactive agent, selected from the group of anthracyclines antibiotics which includes tetracycline, rolitethracycline, minocycline and/or doxycycline and their derivatives, etc..., able to disaggregate or break the amyloid fibrils and/or block the aggregates. This conjugate could contain in its structure one or several targeting moieties, which will provide an effective targeting of the polymer-drug conjugate to the selected diseased area for drug activity, increasing the therapeutic efficacy in the treatment of amyloidosis related diseases, including amyloidosis related to polyneuropathic disorders and neurodegenerative diseases like FAP and AD.
本发明涉及新型聚合物共轭物,其中至少连接有纤维破坏剂和/或聚集体阻断剂,以及附加的靶向基团和/或治疗和诊断探针。在聚合物药物共轭物中,聚合物平台运输至少一种
生物活性物质,选自包括
四环素、罗利
四环素、
米诺环素和/或多西环素及其衍
生物等
蒽环素类抗生素,能够分散或破坏淀粉样纤维和/或阻断聚集体。该共轭物可以在其结构中包含一个或多个靶向基团,这将为药物活性提供有效的靶向,增加治疗淀粉样变性相关疾病的治疗效果,包括与多发性神经病变和神经退行性疾病相关的淀粉样变性。